261 related articles for article (PubMed ID: 19525456)
1. (18)F-FDG and (18)F-FLT uptake early after cyclophosphamide and mTOR inhibition in an experimental lymphoma model.
Brepoels L; Stroobants S; Verhoef G; De Groot T; Mortelmans L; De Wolf-Peeters C
J Nucl Med; 2009 Jul; 50(7):1102-9. PubMed ID: 19525456
[TBL] [Abstract][Full Text] [Related]
2. 18F-FLT PET as a surrogate marker of drug efficacy during mTOR inhibition by everolimus in a preclinical cisplatin-resistant ovarian tumor model.
Aide N; Kinross K; Cullinane C; Roselt P; Waldeck K; Neels O; Dorow D; McArthur G; Hicks RJ
J Nucl Med; 2010 Oct; 51(10):1559-64. PubMed ID: 20847160
[TBL] [Abstract][Full Text] [Related]
3. FLT-PET is superior to FDG-PET for very early response prediction in NPM-ALK-positive lymphoma treated with targeted therapy.
Li Z; Graf N; Herrmann K; Jünger A; Aichler M; Feuchtinger A; Baumgart A; Walch A; Peschel C; Schwaiger M; Buck A; Keller U; Dechow T
Cancer Res; 2012 Oct; 72(19):5014-24. PubMed ID: 22875026
[TBL] [Abstract][Full Text] [Related]
4. Monitoring antiproliferative responses to kinase inhibitor therapy in mice with 3'-deoxy-3'-18F-fluorothymidine PET.
Waldherr C; Mellinghoff IK; Tran C; Halpern BS; Rozengurt N; Safaei A; Weber WA; Stout D; Satyamurthy N; Barrio J; Phelps ME; Silverman DH; Sawyers CL; Czernin J
J Nucl Med; 2005 Jan; 46(1):114-20. PubMed ID: 15632041
[TBL] [Abstract][Full Text] [Related]
5. Effect of corticosteroids on 18F-FDG uptake in tumor lesions after chemotherapy.
Brepoels L; Stroobants S; Vandenberghe P; Spaepen K; Dupont P; Nuyts J; Bormans G; Mortelmans L; Verhoef G; De Wolf-Peeters C
J Nucl Med; 2007 Mar; 48(3):390-7. PubMed ID: 17332616
[TBL] [Abstract][Full Text] [Related]
6. 3'-deoxy-3'-[18F]fluorothymidine as a new marker for monitoring tumor response to antiproliferative therapy in vivo with positron emission tomography.
Barthel H; Cleij MC; Collingridge DR; Hutchinson OC; Osman S; He Q; Luthra SK; Brady F; Price PM; Aboagye EO
Cancer Res; 2003 Jul; 63(13):3791-8. PubMed ID: 12839975
[TBL] [Abstract][Full Text] [Related]
7. Changes in tumor metabolism as readout for Mammalian target of rapamycin kinase inhibition by rapamycin in glioblastoma.
Wei LH; Su H; Hildebrandt IJ; Phelps ME; Czernin J; Weber WA
Clin Cancer Res; 2008 Jun; 14(11):3416-26. PubMed ID: 18519772
[TBL] [Abstract][Full Text] [Related]
8. [Correlation of 3'-deoxy-3'-18F-fluorothymidine uptake to cell proliferation in lung carcinoma xenografts].
Liu X; Zhou NK; Zhang JM; Liang ZY; Zheng X
Ai Zheng; 2006 Dec; 25(12):1512-6. PubMed ID: 17166377
[TBL] [Abstract][Full Text] [Related]
9. [(18)F]FDG PET monitoring of tumour response to chemotherapy: does [(18)F]FDG uptake correlate with the viable tumour cell fraction?
Spaepen K; Stroobants S; Dupont P; Bormans G; Balzarini J; Verhoef G; Mortelmans L; Vandenberghe P; De Wolf-Peeters C
Eur J Nucl Med Mol Imaging; 2003 May; 30(5):682-8. PubMed ID: 12601498
[TBL] [Abstract][Full Text] [Related]
10. Differential (18)F-FDG and 3'-deoxy-3'-(18)F-fluorothymidine PET responses to pharmacologic inhibition of the c-MET receptor in preclinical tumor models.
Cullinane C; Dorow DS; Jackson S; Solomon B; Bogatyreva E; Binns D; Young R; Arango ME; Christensen JG; McArthur GA; Hicks RJ
J Nucl Med; 2011 Aug; 52(8):1261-7. PubMed ID: 21764800
[TBL] [Abstract][Full Text] [Related]
11. Imaging proliferation in brain tumors with 18F-FLT PET: comparison with 18F-FDG.
Chen W; Cloughesy T; Kamdar N; Satyamurthy N; Bergsneider M; Liau L; Mischel P; Czernin J; Phelps ME; Silverman DH
J Nucl Med; 2005 Jun; 46(6):945-52. PubMed ID: 15937304
[TBL] [Abstract][Full Text] [Related]
12. [18F]FLT is superior to [18F]FDG for predicting early response to antiproliferative treatment in high-grade lymphoma in a dose-dependent manner.
Graf N; Herrmann K; Numberger B; Zwisler D; Aichler M; Feuchtinger A; Schuster T; Wester HJ; Senekowitsch-Schmidtke R; Peschel C; Schwaiger M; Keller U; Dechow T; Buck AK
Eur J Nucl Med Mol Imaging; 2013 Jan; 40(1):34-43. PubMed ID: 23053327
[TBL] [Abstract][Full Text] [Related]
13. Selectivity of 18F-FLT and 18F-FDG for differentiating tumor from inflammation in a rodent model.
van Waarde A; Cobben DC; Suurmeijer AJ; Maas B; Vaalburg W; de Vries EF; Jager PL; Hoekstra HJ; Elsinga PH
J Nucl Med; 2004 Apr; 45(4):695-700. PubMed ID: 15073267
[TBL] [Abstract][Full Text] [Related]
14. Temsirolimus combined with cisplatin or bevacizumab is active in osteosarcoma models.
Fleuren ED; Versleijen-Jonkers YM; Roeffen MH; Franssen GM; Flucke UE; Houghton PJ; Oyen WJ; Boerman OC; van der Graaf WT
Int J Cancer; 2014 Dec; 135(12):2770-82. PubMed ID: 24771207
[TBL] [Abstract][Full Text] [Related]
15. [18F]FLT-PET and [18F]FDG-PET in the evaluation of radiotherapy for laryngeal cancer.
Been LB; Hoekstra HJ; Suurmeijer AJ; Jager PL; van der Laan BF; Elsinga PH
Oral Oncol; 2009 Dec; 45(12):e211-5. PubMed ID: 19692292
[TBL] [Abstract][Full Text] [Related]
16. Imaging proliferation in lung tumors with PET: 18F-FLT versus 18F-FDG.
Buck AK; Halter G; Schirrmeister H; Kotzerke J; Wurziger I; Glatting G; Mattfeldt T; Neumaier B; Reske SN; Hetzel M
J Nucl Med; 2003 Sep; 44(9):1426-31. PubMed ID: 12960187
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of 3'-deoxy-3'-18F-fluorothymidine for monitoring tumor response to radiotherapy and photodynamic therapy in mice.
Sugiyama M; Sakahara H; Sato K; Harada N; Fukumoto D; Kakiuchi T; Hirano T; Kohno E; Tsukada H
J Nucl Med; 2004 Oct; 45(10):1754-8. PubMed ID: 15471845
[TBL] [Abstract][Full Text] [Related]
18. Therapy response monitoring of the early effects of a new BRAF inhibitor on melanoma xenograft in mice: evaluation of (18) F-FDG-PET and (18) F-FLT-PET.
Geven EJ; Evers S; Nayak TK; Bergström M; Su F; Gerrits D; Franssen GM; Boerman OC
Contrast Media Mol Imaging; 2015; 10(3):203-10. PubMed ID: 25204436
[TBL] [Abstract][Full Text] [Related]
19. Early assessment of therapy response in malignant lymphoma with the thymidine analogue [18F]FLT.
Buck AK; Kratochwil C; Glatting G; Juweid M; Bommer M; Tepsic D; Vogg AT; Mattfeldt T; Neumaier B; Möller P; Reske SN
Eur J Nucl Med Mol Imaging; 2007 Nov; 34(11):1775-82. PubMed ID: 17541585
[TBL] [Abstract][Full Text] [Related]
20. 3'-[18F]fluoro-3'-deoxythymidine ([18F]-FLT) as positron emission tomography tracer for imaging proliferation in a murine B-Cell lymphoma model and in the human disease.
Wagner M; Seitz U; Buck A; Neumaier B; Schultheiss S; Bangerter M; Bommer M; Leithäuser F; Wawra E; Munzert G; Reske SN
Cancer Res; 2003 May; 63(10):2681-7. PubMed ID: 12750297
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
